Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Smoking, GAD65 autoimmunity, genetic susceptibility to type 1 diabetes and incident adult-onset diabetes in the EPIC-InterAct case-cohort study.

Metabologia·2026
Same author

Deleterious Effects of a GAD65 Monoclonal Autoantibody on Islet Function.

Diabetes·2025
Same author

GAD65Abs Are Not Associated With Beta-Cell Dysfunction in Patients With T2D in the GRADE Study.

Journal of the Endocrine Society·2024
Same author

Type 1 Diabetes Genetic Risk Score Differentiates Subgroups of Ketosis-Prone Diabetes.

Diabetes care·2023
Same author

Subgroups of adult-onset diabetes: a data-driven cluster analysis in a Ghanaian population.

Scientific reports·2023
Same author

Interaction between plasma phospholipid odd-chain fatty acids and GAD65 autoantibodies on the incidence of adult-onset diabetes: the EPIC-InterAct case-cohort study.

Diabetologia·2023

Related Experiment Video

Updated: Jun 24, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Engineered antibodies for type 1 diabetes.

Christiane S Hampe1

  • 1University of Washington, Department of Medicine, 815 Mercer Street, Seattle, WA 98109, USA. champe@u.washington.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|April 2, 2009
PubMed
Summary
This summary is machine-generated.

Engineered monoclonal antibodies (mAbs) offer promising therapeutic strategies for type 1 diabetes (T1D) by targeting disease mechanisms. Antibody engineering enhances efficacy for potential T1D treatments, moving towards a cure.

More Related Videos

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Related Experiment Videos

Last Updated: Jun 24, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Area of Science:

  • Immunology and Endocrinology
  • Biotechnology and Antibody Engineering

Background:

  • Type 1 Diabetes (T1D) management relies on insulin replacement therapy, which is not a cure and has limitations in preventing long-term complications.
  • Current treatments do not fully replicate the body's natural insulin response, necessitating continuous glucose monitoring and insulin administration.
  • A definitive cure for T1D is needed to free patients from daily management burdens.

Purpose of the Study:

  • To review the application of engineered monoclonal antibodies (mAbs) in the treatment of Type 1 Diabetes (T1D).
  • To discuss various antibody engineering approaches aimed at enhancing therapeutic efficacy for T1D.
  • To explore the potential of mAbs as immunomodulatory agents in T1D pathogenesis.

Main Methods:

  • Review of existing literature on monoclonal antibody (mAb) engineering techniques.
  • Analysis of different strategies for modifying antibody properties (size, effector function, immunogenicity).
  • Examination of the application of engineered mAbs in preclinical and clinical studies for T1D.

Main Results:

  • Monoclonal antibodies (mAbs) demonstrate high target specificity, making them valuable for diagnosing and treating T1D.
  • Antibody engineering can significantly improve the efficacy of mAbs by optimizing their characteristics.
  • Engineered mAbs show potential for targeted immunomodulation in T1D pathogenesis.

Conclusions:

  • Engineered monoclonal antibodies (mAbs) represent a promising avenue for developing novel immunotherapies for Type 1 Diabetes (T1D).
  • Further advancements in antibody engineering are crucial for maximizing therapeutic benefits and potentially achieving a cure for T1D.
  • Targeted manipulation of T1D pathogenesis using engineered mAbs could lead to improved patient outcomes and independence from conventional therapies.